DSM-Firmenich AG
AEX:DSFIR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
67.8
107.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
DSM-Firmenich AG
DSM-Firmenich AG is the culmination of a merger between two titans in their respective fields: DSM, a Dutch multinational known for its prowess in health, nutrition, and sustainable living, and Firmenich, a Swiss firm renowned for its legacy in fragrances and flavors. This strategic union blends DSM's strengths in innovative biotechnology and sustainability with Firmenich's expertise in creating unique sensory experiences. As a combined entity, DSM-Firmenich AG operates on the cutting edge of scientific innovation, catering to a diverse array of industries including food and beverages, personal care, and health products. The synergy of DSM's leadership in sustainable solutions with Firmenich's artistry in scent and flavor not only results in high-quality consumer products but also pushes the envelope in terms of environmental responsibility and human health.
The company's business model thrives on innovation and a deep understanding of consumer needs. It leverages its extensive research and development capabilities to produce solutions that enhance the taste, texture, and nutritional value of food, alongside creating signature scents for personal and home care products. By consistently investing in technology and sustainable practices, DSM-Firmenich generates revenue through a broad portfolio of offerings that cater to global clients ranging from multinational corporations to niche brands. Their growth is anchored in delivering products that resonate with consumers' increasing demands for sustainability and authenticity, ensuring that every product not only meets the highest standards of quality but also aligns with the values of a rapidly changing world.
DSM-Firmenich AG is the culmination of a merger between two titans in their respective fields: DSM, a Dutch multinational known for its prowess in health, nutrition, and sustainable living, and Firmenich, a Swiss firm renowned for its legacy in fragrances and flavors. This strategic union blends DSM's strengths in innovative biotechnology and sustainability with Firmenich's expertise in creating unique sensory experiences. As a combined entity, DSM-Firmenich AG operates on the cutting edge of scientific innovation, catering to a diverse array of industries including food and beverages, personal care, and health products. The synergy of DSM's leadership in sustainable solutions with Firmenich's artistry in scent and flavor not only results in high-quality consumer products but also pushes the envelope in terms of environmental responsibility and human health.
The company's business model thrives on innovation and a deep understanding of consumer needs. It leverages its extensive research and development capabilities to produce solutions that enhance the taste, texture, and nutritional value of food, alongside creating signature scents for personal and home care products. By consistently investing in technology and sustainable practices, DSM-Firmenich generates revenue through a broad portfolio of offerings that cater to global clients ranging from multinational corporations to niche brands. Their growth is anchored in delivering products that resonate with consumers' increasing demands for sustainability and authenticity, ensuring that every product not only meets the highest standards of quality but also aligns with the values of a rapidly changing world.
Performance Overview: Perfumery & Beauty and Taste, Texture & Health performed well despite a volatile macro environment, while Animal Nutrition & Health faced significant challenges.
Synergies: Management expressed increased confidence in achieving €350 million in merger synergies, particularly cost synergies, now that detailed integration work is underway.
Guidance: Year-end net debt is expected at €3.4–3.5 billion (excluding hybrid), around 2x pro forma EBITDA. Full-year EBITDA outlook remains €1.8 to €1.9 billion.
Vitamin Business Headwinds: Vitamin E prices declined further since last update, but additional downside is already factored into guidance.
Volumes & Destocking: Volumes in key divisions were weak, mainly due to destocking and specific site closures (e.g., Pinova). Some volume improvement is only expected in Q4 as destocking fades.
Cash Flow & Working Capital: Working capital and cash conversion were weak in H1, with focus on improvement back toward previous levels.
Leadership Transition: Geraldine Matchett is stepping down as CFO, with Ralf Schmeitz taking over from September 1.